Granules India's net profit up 26 pc to Rs 41 cr in Q2

Pharmaceutical firm Granules India today announced 26 per cent jump in net profit at Rs 41 crore in the quarter ended September 30 as compared to Rs 32 crore in the corresponding period a year ago.
The company's revenue increased by 3 per cent at Rs 364 crore as compared to Rs 353 crore in the corresponding period, a company statement said here.
"We are focused to achieve our long-term goals as we move ahead in the investment phase. Our API and PFI capacity enhancements within our base business and Greenfield API facility in Vizag are both on track," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said.

We are also happy to see an increasing share of revenue
coming from our formulation division which focuses on the U.S., European and Canadian markets," said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director.
About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)
Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia.

Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.
Caution Statement:
Certain statements made above may be 'forward looking statements' within the meaning of applicable laws and regulations.
Media Contact
Sumanta Bajpayee
Sumanta.Bajpayee@granulesindia.Com
+91-40-30663572
Granules India Ltd.
Source: Granules India Ltd.